PMID- 21437912
OWN - NLM
STAT- MEDLINE
DCOM- 20111129
LR  - 20181201
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
VI  - 104
IP  - 6
DP  - 2011 Nov 1
TI  - Epidermal growth factor receptor overexpression in malignant pleural 
      mesothelioma: prognostic correlations.
PG  - 701-5
LID - 10.1002/jso.21901 [doi]
AB  - BACKGROUND: To evaluate epidermal growth factor receptor (EGFR) phenotypic 
      expression and related gene status in malignant pleural mesothelioma (MPM) and to 
      correlate the results with patients' prognosis. METHOD: Eighty-three cases of MPM 
      specimens were submitted to immunohistochemical (IHC) staining to evaluate the 
      expression of EGFR protein; positive cases were submitted to fluorescence in situ 
      hybridization (FISH) to investigate the gene status. Results were correlated with 
      clinico-pathological characteristics and long-term survival. RESULTS: 
      Thirty-eight cases (46%) demonstrated a positive IHC reaction [30/57 (52%) 
      epithelial and 8/20 (40%) biphasic whereas sarcomatous MPM were negative]. No 
      association was recorded between EGFR IHC positive staining and age, gender, or 
      asbestos exposure. Three out of 38 (8%) cases submitted to FISH were positive 
      revealing gene amplification or polysomy. Mean follow-up was 15.4  months (range 
      2-44). Epithelial subtype only was confirmed to affect prognosis (2-years 
      survival rate 40 vs. 18% for non-epithelial subtype, P = 0.042). When epithelial 
      MPM patients were considered, IHC EGFR positive staining was demonstrated to be a 
      negative prognostic factor (2-years survival rate 26 vs. 60% for IHC EGFR 
      negative staining; P = 0.026). CONCLUSIONS: EGFR overexpression is identified by 
      IHC in 52% of epithelial MPM and is demonstrated to be a factor negatively 
      affecting prognosis. Phenotypic overexpression seems not to be related to gene 
      status alteration.
CI  - Copyright (c) 2011 Wiley Periodicals, Inc.
FAU - Rena, Ottavio
AU  - Rena O
AD  - Thoracic Surgery Unit, University of Eastern Piedmont, Azienda 
      Ospedaliero-Universitaria Maggiore della Carita, C.so Mazzini, 18, Novara, Italy. 
      ottaviorena@libero.it
FAU - Boldorini, Luciano R
AU  - Boldorini LR
FAU - Gaudino, Erica
AU  - Gaudino E
FAU - Casadio, Caterina
AU  - Casadio C
LA  - eng
PT  - Journal Article
DEP - 20110321
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - ErbB Receptors/*genetics/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Amplification
MH  - Gene Dosage
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mesothelioma/*genetics/metabolism/pathology
MH  - Mutation/genetics
MH  - Pleural Effusion, Malignant/*genetics/metabolism/pathology
MH  - Pleural Neoplasms/*genetics/metabolism/pathology
MH  - Prognosis
MH  - Survival Rate
EDAT- 2011/03/26 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/03/26 06:00
PHST- 2010/11/08 00:00 [received]
PHST- 2011/02/01 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1002/jso.21901 [doi]
PST - ppublish
SO  - J Surg Oncol. 2011 Nov 1;104(6):701-5. doi: 10.1002/jso.21901. Epub 2011 Mar 21.